Could Obama end FDA preemption by executive order?
The Center for Progressive Reform Protecting Public Health and the Environment by the Stroke of a Presidential Pen: Seven Executive Orders for the President's First 100 Days,"
As CPR's Blog describes,
Through Executive Orders, a President exercises his b
RxP Weekly Reader #36
MedPac approves disclosure recs
Last week, the Medicare Payment Advisory Commission approved recommendations that would require pharmaceutical and medical device companies to disclose payments to clinicians, academic medical centers, continuing medical ed
MedPAC to vote on pharmaceutical disclosure recommendations
Tomorrow, the Medicare Payment Advisory Commission will vote on final recommendations to Congress for a public reporting system of physicians’ financial relations with drug and device manufacturers.
A draft version of the recommendations, laid out in a Ju
The End of AWP? Wal-Mart and Caterpillar bid AWP "goodbye"
Drug Benefit News brings us this fascinating story: Caterpillar/Wal-Mart Rx Drug Pilot Scraps Use of Average Wholesale Price, Uses Drug Cost-Plus Pricing.
Readers of this blog know that we are prone to getting on a soapbox about the flawed "Average Whol
Early reports from today's Supreme Court hearing in Wyeth v. Levine
Tomorrow we'll all be glued to our TVs, radios, computer screens, teletypes and telegraphs for news of the Election. But today it's all about Wyeth v. Levine, the critical case addressing whether consumers' lawsuits against drug companies for failing to
Latest state AWP settlement: Schering-Plough to pay Missouri $31M
Numerous state Attorneys General have filed lawsuits against pharmaceutical companies for allegedly fraudulently inflating the "Average Wholesale Price" of prescription drugs that states pay for on behalf of Medicaid recipients. The "Average Wholesale Pr
Prescription Project Director Op-Ed: "Let public see doctors’ ties to drug companies"
Prescription Access Litigation's parent organization, Community Catalyst, is also home to The Prescription Project, which works to eliminate conflicts of interest created by pharmaceutical industry marketing by promoting policy change among academic medic
RxP Weekly Reader: Jack-O-lection Edition #35
Pre-pre-emption report shows divide in FDA over labeling regs
Several top FDA officials objected to the agency’s rewrite of labeling rules in 2006 and 2008, which have made it harder for drug companies to include new safety risks on drug labels and thus b
PAL welcomes our newest coalition member: Minnesota State Retiree Council, AFL-CIO
Prescription Access Litigation is pleased to welcome the newest member of our coalition, the Minnesota State Retiree Council, AFL-CIO.
The Council is the umbrella organization of union retirees clubs and local unions with retirees throughout Minnesota. I